Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

ere published in The New England Journal of Medicine in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile infection," in the February 3, 2011 issue.
  • New Drug Application for fidaxomicin for the treatment of CDI was accepted by the U.S. Food and Drug Administration (FDA) for filing and received a six-month priority review. The FDA plans to discuss the NDA at a meeting of its Anti-Infective Drugs Advisory Committee currently scheduled for April 5, 2011 and also assigned a Prescription Drug User Fee Act goal date of May 30, 2011.
  • Patent which covers additional dosage forms of fidaxomicin was issued by the U.S. Patent and Trademark Office.
  • Strengthened the management team in preparation for the potential commercial launch of fidaxomicin with the appointments of Gregory E. Papaz, as Senior Vice President of U.S. Commercial Operations, Kurt M. Hartman, as General Counsel and Senior Vice President of Access, Linda Amper, Ph.D., as Senior Vice President of Human Resources, Hemal Shah as Senior Vice President of Health, Economics & Outcomes Research (HEOR), John Womelsdorf, Ph.D., as Vice President of Business Development and most recently, Glenn S. Tillotson, Ph.D., as Senior Vice President of Medical Affairs.  
  • Announced appointment of former Chief Executive Officer and Chairman of the Board of Directors of Pfizer, Hank McKinnell, Ph.D. to Optimer's Board of Directors.
  • Optimer's Marketing Authorization Application (MAA) for fidaxomicin for the treatment of CDI was accepted for review by the European Medicines Agency (EMA).
  • A publication in the peer-reviewed journal, Microbiology, a journal of the Society for General Microbiology, highlighted fidaxomicin's narrow spectrum of activity and minimal disruption of microflora in patients with CDI compared to vancomycin.
  • Combined data from Optimer's two fidaxomicin Phase 3 trials in patients with CDI was prese
    '/>"/>

  • SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
    9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
    10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
    11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
    (Date:12/24/2014)... 2014  Medical Science Liaisons play a large role ... the medical device industry and key stakeholders, the role ... years as the device industry relies on them to ... by benchmarking firm, Best Practices, LLC, one area where ... is by harnessing new technology to enable education. Online ...
    (Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
    Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
    ... A of Trial Assessing Regimen of ... TUSTIN, Calif., Oct. 7 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... for the treatment of cancer and,hepatitis C virus (HCV) ... first stage of a Phase II trial of bavituximab ...
    ... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
    Cached Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
    (Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
    (Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
    (Date:12/25/2014)... News) -- The risk of burns from fires and ... to be extra cautious, an expert says. "Between ... increase in patients coming in with burns," said Dr. ... Firefighters Burn Center of Stony Brook University Hospital in ... joy, but if not careful, could quickly turn tragic," ...
    (Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
    (Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
    Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
    ... deliveries a possible cause, study suggests, , , WEDNESDAY, Jan. ... of women giving birth experience severe complications, a new ... between 1998 and 2005. , Problems such as blood ... need for blood transfusions rose from 0.64 percent in ...
    ... 2009) The American Gastroenterological Association (AGA) Institute journal, ... journal with the most impact on the field of ... Science Indicators data by Thompson Reuters. This impact was ... any clinical medical journal. The current citation record for ...
    ... study appearing in The Prostate has found that ... as MV-CEA, may prove to be an effective treatment for ... type of treatment, called virotherapy, can effectively infect, replicate in ... a leading cause death among males in the western world. ...
    ... AUSTIN, Texas, Jan. 21 Alliance Tech ... measurement utilizing RFID, announced today that Carestream ... measurement technologies to identify additional lead opportunities ... North America (RSNA) conference held in Chicago ...
    ... and Germany pledge critically needed funds and urge ... crippling childhood diseaseSAN DIEGO, Jan. 21 Rotary ... the British and German governments today committed more ... polio, a crippling and sometimes fatal disease that ...
    ... and services, announced that Maggie O,Hara, IVANS group vice president of ... finalist in the fifth annual Women of Innovation awards program hosted ... ... (Vocus) January 21, 2009 -- IVANS, Inc. , a leading ...
    Cached Medicine News:Health News:Severe Obstetric Complications on the Increase 2Health News:Severe Obstetric Complications on the Increase 3Health News:Clinical Gastroenterology and Hepatology most influential journal in field of clinical medicine 2Health News:Measles virus may be effective prostate cancer treatment 2Health News:Alliance Tech's RFID Technology Enhances Carestream Health's Capability to Connect with Key Prospects at RSNA 2Health News:Alliance Tech's RFID Technology Enhances Carestream Health's Capability to Connect with Key Prospects at RSNA 3Health News:Global Health Community Commits Over $630 Million in Aggressive Push for Polio Eradication 2Health News:Global Health Community Commits Over $630 Million in Aggressive Push for Polio Eradication 3Health News:Global Health Community Commits Over $630 Million in Aggressive Push for Polio Eradication 4Health News:Maggie O'Hara Named as a Finalist in Connecticut Technology Council's Women of Innovation Awards Program 2Health News:Maggie O'Hara Named as a Finalist in Connecticut Technology Council's Women of Innovation Awards Program 3
    ... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
    The NeurOptics Pupillometer is a portable instrument used to measure pupils to screen candidates for refractive procedures and other ophthalmic applications....
    ... system features an advanced design that accommodates ... system gives surgeons the flexibility to easily ... Flexibility is built-in to every aspect of ... innovative Secure-TwistTM anti-migration system to the screw ...
    ... The SC-Acufix anterior cervical plate system is ... patented, integrated swivel, which provides for consistent, ... prevents bone screw disengagement or backout. This ... secondary locking screw. Simply implant your screws ...
    Medicine Products: